Zacks Research Has Positive Outlook of Medifast Q3 Earnings

Medifast Inc (NYSE:MED) – Analysts at Zacks Research increased their Q3 2026 earnings per share estimates for Medifast in a report issued on Monday, August 24th. Zacks Research analyst Team now forecasts that the specialty retailer will post earnings of ($0.40) per share for the quarter, up from their previous estimate of ($0.60). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Medifast’s current full-year earnings is ($1.00) per share. Zacks Research also issued estimates for Medifast’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.04) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.47) EPS, Q1 2028 earnings at ($0.16) EPS, Q2 2028 earnings at ($0.11) EPS and FY2028 earnings at ($0.43) EPS.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS.

Separately, Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medifast presently has a consensus rating of “Reduce” and an average target price of $12.00.

Medifast Price Performance

Shares of Medifast stock opened at $12.20 on Wednesday. Medifast has a 1 year low of $9.22 and a 1 year high of $14.67. The company has a market capitalization of $136.34 million, a P/E ratio of -5.23 and a beta of 0.65. The business has a 50 day moving average price of $10.94 and a 200 day moving average price of $11.07.

Institutional Trading of Medifast

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its stake in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP bought a new stake in Medifast during the third quarter worth approximately $37,000. Intesa Sanpaolo Wealth Management acquired a new stake in Medifast in the fourth quarter worth approximately $47,000. State of Wyoming bought a new position in Medifast during the 4th quarter valued at $59,000. Finally, Strs Ohio bought a new position in Medifast during the 1st quarter valued at $78,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Insider Transactions at Medifast

In related news, Director Parsa Kiai purchased 43,150 shares of Medifast stock in a transaction dated Thursday, August 20th. The shares were acquired at an average price of $11.60 per share, with a total value of $500,540.00. Following the completion of the transaction, the director owned 661,306 shares of the company’s stock, valued at approximately $7,671,149.60. This trade represents a 6.98% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by corporate insiders.

Key Stories Impacting Medifast

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to -$1.04 from -$1.97, FY2027 to -$0.47 from -$1.89, and FY2028 to -$0.43 from -$1.81. These sizable upgrades indicate improving expectations for Medifast’s profitability and could provide support for the stock.
• Positive Sentiment: Quarterly estimates were also lifted, including Q3 2026 EPS to -$0.40 from -$0.60, Q4 2026 to -$0.17 from -$0.50, Q2 2027 to -$0.12 from -$0.66, Q3 2027 to -$0.10 from -$0.58, and Q4 2027 to -$0.08 from -$0.48. Q2 2028 was raised to -$0.11 from -$0.64.
• Neutral Sentiment: Zacks maintained a Hold rating. Its current full-year consensus remains approximately -$1.00 EPS, broadly consistent with the revised FY2026 forecast of -$1.04.
• Negative Sentiment: Despite the upgrades, Medifast is still expected to report losses through FY2028. Zacks also trimmed its Q1 2028 EPS forecast slightly to -$0.16 from -$0.15, highlighting continued uncertainty around the pace of recovery.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.